CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquires Oncotest GmbH
Snapshot
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired Oncotest GmbH for $36.0 million in November 2015. The transaction was structured as all cash. Oncotest GmbH is a Germany-based Discovery and Safety Assessment (DSA) — In Vivo Discovery business.
- Acquirer
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- Target
- Oncotest GmbH
- Value
- $36.0 million
- Date
- November 2015
- Type
- full acquisition
- Status
- ready
The deal at a glance
About this deal
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired Oncotest GmbH for $36.0 million, a transaction completed in November 2015, structured as all cash.
Oncotest GmbH operates in Discovery and Safety Assessment (DSA) — In Vivo Discovery, is based in Germany. Oncotest GmbH was a Germany-based CRO providing discovery services for oncology, with patient-derived xenograft (PDX) and syngeneic models.
The purpose of this acquisition was to expand our oncology services capabilities, enabling us to provide clients with access to a more comprehensive portfolio of technologies, including patient-derived xenograft (PDX) and syngeneic models. The preliminary purchase price for Oncotest was $36.0 million.
In Vivo Discovery business, DSA segment
No advisory firms have been disclosed for this transaction.